In vivo imaging of the pancreas, pancreatic tumors and metastases.

<p>(<b>A</b>) Experimental design. (<b>B</b>) MRI of a control mouse pancreas and liver. P: pancreas, S: stomach, Sp: spleen, K: kidney, L: liver, G: gallbladder. (<b>C</b>) Large pancreatic mass (T), but no metastatic lesions in a KPC mouse. (<b>D</b>) Two iKras*p53* mice on doxy 15 weeks (left) and 42 weeks (right) show a large pancreatic mass and liver metastases. (<b>E</b>) Identification of smaller tumors (iKras*p53* #3, left panel, 38 weeks) can be monitored as they develop into larger tumors (iKras*p53* #3, right panel, 40weeks). (<b>F</b>) Volume measurements of both primary tumors and combined metastases for individual KPC and iKras*p53* animals at the indicated time points.</p

Longitudinal imaging of pancreatic tumor growth and regression.

<p>(<b>A</b>) Experimental design. (<b>B</b>) MRI taken at 38 weeks after Kras* activation shows normal pancreas morphology. P: pancreas, S: stomach, Sp: spleen. However, in the same animal, there is evidence of a small pancreatic tumor (T) at 40weeks, 2 days, which continues to increase in size over the next four weeks. (<b>C</b>) Tumor regression occurs following Kras* inactivation. By three weeks, there is no longer an identifiable tumor mass. (<b>D</b>) Tumor volume at the indicated time points. (<b>E</b>) Gross morphology of the pancreas following Kras* inactivation - note the small pancreas with no evident tumor mass (left panel). Histology of the regressed tissue (HE, middle panel, Scale bar 100 um) reveals acini (red arrowhead) surrounded by fibrosis (green arrowhead) and adipose tissue (blue arrowhead) with dilated ducts (yellow arrowhead) containing some cells that exhibit mucin accumulation identified by arrows (PAS staining, right panel, Scale bar 20 um). (<b>F</b>) Histology of fibrotic cysts, indicating a possible previous tumor site (HE, left panel), are lined with cells that are CK19 positive (inset). Scale bar 100 um. Gomori Trichrome (Scale bar 100 um), SMA staining (inset), p-ERK1/2, and Ki67 staining indicate that the remaining fibrosis is no longer reactive. Scale bars 20 um.</p

Pancreatic tumor relapse occurs following Kras* reactivation.

<p>(<b>A</b>) Experimental design. (<b>B</b>) Identification of a large pancreatic tumor mass 22 weeks after Kras* activation. T: tumor, S: stomach, Sp: spleen, L: liver, G: gallbladder. (<b>C</b>) Images taken 1, 3 and 6 weeks following Kras* inactivation. Note the greatly reduced primary tumor mass and metastatic load. (<b>D</b>) Reactivation of Kras* results in rapid tumor relapse. (<b>E</b>) Histology of the primary tumor as well as metastases found in the liver and lung following tumor relapse show abundant phospho-ERK1/2 expression (insets). Scale bar 100 um (<b>F</b>) Tumor and total metastases volume at the indicated time points.</p

Pathology of iKras*p53* mice.

<p><b>Histological Grade</b> - W: well differentiated; M: moderately differentiated; P: poorly differentiated; U: undifferentiated (sarcomatoid).</p><p><b>Presence of Metastasis</b> - Y: yes; N: no; –: not available.</p

Characterization of primary pancreatic cancer cell lines from iKras*p53* mice.

<p>(<b>A</b>) Primary cell line iKras*p53*-1 exhibits epithelial morphology and demonstrates doxycycline dependent Kras* expression (* p<0.05), and pERK1/2 levels at passage 5. (<b>B</b>) The same cell line at passage 12; Kras* expression is still dependent on doxy (*** p<0.001), but pERK1/2 levels do not depend on Kras* expression. (<b>C</b>) A second primary cell line, iKras*p53*-2, has mesenchymal morphology. At passage 6, Kras* expression is dependent on doxy (** p<0.01), and pERK1/2 levels depend on Kras* expression. (<b>D</b>) Analysis at passage 11: Kras* is still regulated by doxy (* p<0.05, ** p<0.01), but pERK1/2 levels remain elevated. (<b>E</b>) Western blot analysis of apoptosis, indicated by cleaved caspase-3 (CC3), and proliferation, measured by proliferating cell nuclear antigen (PCNA), in both iKras*p53*-1 and iKras*p53*-2 cell lines. (<b>F</b>) Immunofluorescence of apoptosis, indicated by cleaved caspase-3 (CC3), in iKras*p53*-2 cells either in the presence of (+48 h) or absence (−48 h) of doxy in the media. DAPI staining marks the nuclei. Scale bar 100 um. (<b>G</b>) Ras pull-down assay demonstrates that Ras activity levels are comparable between iKras*p53* cell lines and cells from KPC tumors.</p

iKras*p53* cells reactivate Kras* expression independently of doxycycline regulation.

<p>(<b>A</b>) Tumor volume measured over time for iKras*p53*-1 cells transplanted subcutaneously in NOD/SCID mice. The yellow line indicates the presence of doxy, black lines indicate the absence of doxy, arrows indicate harvest time-points. N = 5. (<b>B</b>) Histology and phospho-ERK1/2 expression (inset) of iKras*p53*-1 tumors harvested during the initial growth phase and of relapsed tumors. Scale bar 100 um. (<b>C</b>) Tumor formation, regression, and relapse in NOD/SCID mice injected subcutaneously with primary cell line iKras*p53*-2. N = 5. A second cohort of NOD/SCID mice were injected with iKras*p53*-2 cells, but maintained in the absence of doxy which do not develop tumors. N = 10. The yellow line indicates the presence of doxy, black lines indicate the absence of doxy, arrows indicate harvest time-points. (<b>D</b>) Histology and pERK1/2 (inset), Ki67 and SMA expression of iKras*p53*-2 tumors during growth, regression, and relapse phases. Scale bar 100 um. (<b>E</b>) Quantitative PCR for oncogenic Kras* and myc expression in iKras*p53*-2 tumors.</p

Characterization of iKras*p53* primary tumor and metastases.

<p>(<b>A</b>) Histology of a primary pancreatic adenocarcinoma and metastases to liver and lung. (<b>B–G</b>) Immunohistochemistry of primary tumor and metastases for: (<b>B</b>) phospho-ERK1/2; (<b>C</b>) CK19; (<b>D</b>) Ki67; (<b>E</b>) p53; (<b>F</b>) γH2AX; (<b>G</b>) αSMA. M: metastasis. Scale bar 20 um.</p

Antibodies

<p>Antibodies</p

<i>In vivo</i> imaging of therapeutic response using contrast enhanced diffusion weighted MRI.

<p>(A) MR gadolinium (Gd) contrast-enhanced T1-weighted images and ADC color overlay maps demonstrate effects of <i>in vivo</i> effects of treatment with obtained from representative control, perifosine, CCI-779 and combination (perifosine + CCI-779) treated glioma mice at 5-7 days post-initiation of therapy. (B) Plot of mean MRI-determined tumor volumes based upon Gd-contrast enhanced regions versus time post-treatment initiation for control, perifosine, CCI-779 and combination (perifosine + CCI-779) treated mice. (Error bars ± SEM). (C) Plot of percent change of mean ADC values versus time post-treatment initiation for control, perifosine, CCI-779 and combination (perifosine + CCI-779) treated mice. (Error bars ± SEM).</p

PDGF-B-driven glimoas treated with the combination of perifosine and CCI-779 undergo cell death and have decreased proliferation.

<p>Images of H&E, IHC with anti-p-S6RP, anti-PCNA, anti-Ki67, and TUNEL of (A) PTEN +/+ and (B) PTEN -/- GBMs after glioma-bearing mice were treated <i>in vivo</i> for 5 days with either vehicle, 30 mg/Kg perifosine, 40 mg/Kg CCI-779, or a combination of 30 mg/Kg perifosine with 40 mg/Kg CCI-779. PCNA and Ki67 images are 200x with the black bar indicating 100 microns. The graph on the right shows quantification of Ki67 and TUNEL staining for 3-4 independent tumors. *,**, and *** represent significance determined by ANOVA analysis for p>0.05, p>0.01, and p>0.001.</p